Industry relief over drugs and water quality compromise in EU
This article was originally published in SRA
There is relief for drug developers in the EU as plans to place three commonly used pharmaceuticals on a priority list of substances affecting water quality have been put on hold. Placing them on the priority list would have resulted in the substances being subjected to strict environmental quality standards or even being phased out were they ultimately to have been deemed hazardous1-4.
You may also be interested in...
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.